

ASX/Media Release

28 October 2019

Results of Annual General Meeting

Perth 28 October 2019: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that the Annual General Meeting of the Company was held today, 28 October 2019. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against
1	Adoption of Remuneration Report (non-binding)	153,953,936	25,796,659
2	Re-election of Director –Mr Robert Towner	244,547,996	25,078,667
3	Re-election of Director –Dr Michael Thurn	245,855,149	23,883,514
4	Re-election of Director –Dr Stewart Washer	244,811,873	24,926,790
5	Ratification of placement to investors under Listing Rule 7.1	212,208,317	2,483,884
6	Ratification of placement to investors under Listing Rule 7.1A	239,023,188	25,575,189
7	Approval of Additional 10% Placement Capacity	241,935,908	27,167,933

Summary of Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Adoption of Remuneration Report (non-binding)	125,272,228	24,956,659	2,169,351	87,090,748
2	Re-election of Director –Mr Robert Towner	212,335,884	24,238,667	2,077,199	837,236
3	Re-election of Director –Dr Michael Thurn	214,281,023	23,043,514	2,077,199	87,250
4	Re-election of Director –Dr Stewart Washer	213,235,747	24,086,790	2,079,199	87,250
5	Ratification of placement to investors under Listing Rule 7.1	181,712,513	1,643,884	98,877	55,133,712
6	Ratification of placement to investors under Listing Rule 7.1A	207,349,432	24,735,189	2,176,829	5,227,536
7	Approval of Additional 10% Placement Capacity	211,112,152	26,327,933	1,929,791	119,110

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (US) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company's focus is the development of safe and effective topical treatments for serious skin diseases, leveraging the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company has announced data from its Phase 2 clinical study and is moving forward with its clinical program with a Phase 2 FDA meeting. A Phase 2 patient study in atopic dermatitis is on target to complete enrolment in 4Q CY2019 with data in 1Q 2020. The Company has successfully completed a mechanism of action study for synthetic cannabidiol in skin disease, with positive data announced in June 2019 and is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol, with first products planned to enter the clinic in 2H CY2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres

Hales² Communications

P: +61 423 139 163

haley@h-squared.com.au